CYH vs IRD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CYH exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio (-0.25), which indicates negative shareholders' equity. While the current P/E ratio appears deceptively low, the surge to a Forward P/E of 20.81 suggests a significant expected collapse in earnings. Revenue is contracting (-6.10% YoY) and the stock is in a persistent technical downtrend, losing 74% of its value over five years. The provided growth-based intrinsic value of $24.08 is fundamentally disconnected from the company's current balance sheet insolvency and should be disregarded.
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. Most alarming is the negative gross margin of -117.05%, meaning the company loses money on every unit of revenue generated before operating expenses. Despite a speculative 654.9% price surge over the last year and a 'strong_buy' analyst consensus, the underlying data shows declining revenue (-10.20%) and extreme valuation multiples (P/B of 24.36). The stock appears to be trading on momentum or speculative expectations rather than any tangible financial health.
Compare Another Pair
Related Comparisons
CYH vs IRD: Head-to-Head Comparison
This page compares Community Health Systems, Inc. (CYH) and Opus Genetics, Inc. (IRD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.